Shots:
The EMA approved 6 New Chemical Entity (NCE) and 6 Biologic Drugs in December 2022, leading to treatments for patients and advances in the healthcare industry
In December 2022, the major highlights drugs were Pluvicto’s approval for progressive PSMA+ metastatic castration resistant prostate cancer, Dupixent for Prurigo Nodularis
PharmaShots has compiled a list of…
INTRODUCTION
Also known as seizure disorder, epilepsy is a non-communicable chronic disorder of the brain and is the fourth most common neurological disease globally. It is a central nervous system (CNS) disorder characterized by recurrent episodes of seizures that are short changes in normal brain activity which led to brief incidences of involuntary movements either…
Shots:
Immunology focuses on analyzing all aspects of the immune system in both healthy and diseased states, from its structure & function to its disorders, blood banking, immunization & organ transplant
Along with the enhanced utilization of immunotherapies for immunological & autoimmune diseases, monoclonal antibodies have also showcased a great potential to be used as…
The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B
The first quarter of the year also showcases regulatory events…
The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, Gilead acquired Immunomedics for ~$21B, Illumina acquired GRAIL for ~$8B, J&J acquired Momenta Pharmaceuticals for $6.5B and Nestlé acquired Aimmune Therapeutics for $2.6B, Sanofi acquired Principia Biopharma for ~$3.68B. Apart from…

